-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Amyloid plaque is a plaque structure formed by abnormal deposits of β-amyloid protein outside brain neurons.
It hinders some functions and eventually leads to neuronal death.
This is also considered a sign of Alzheimer's disease (AD)
.
But amyloid deposition can also occur on the retina of the eye, and it often occurs in patients who are clinically diagnosed with Alzheimer's
diagnosis
In a small cross-sectional study, a research team led by scientists from the University of California San Diego School of Medicine compared amyloid tests in the retina and brain of patients in the two studies, assessing neurodegeneration in people with low amyloid levels.
How big is the risk
.
Researchers have observed that the appearance of retinal spots in the eyes is associated with higher levels of amyloid in brain scans
The appearance of retinal spots in the eyes is associated with higher levels of amyloid in brain scans
Jennifer Ngolab et al, Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring (2021).
DOI: 10.
1002/dad2.
12199
DOI: 10.
1002/dad2.
12199
Compared with the individuals in the longitudinal evaluation test of amyloid risk and neurodegeneration, the four individuals in this test showed more curcumin-positive spots on the retina.
There are obvious differences between the two groups.
Studies on curcumin-labeled amyloid have found that clinical patients have cognitive impairment at an early stage, and retinal inclusions have been observed in preclinical cohort retinal studies
.
The researchers demonstrated that an increase in retinal curcumin-positive spots can be detected in asymptomatic individuals with positive amyloid positron emission tomography
Curcumin binds to amyloid in the body and is used as a contrast agent to identify early cognitive impairment (MCI) and amyloid deposits in the retina of individuals with mild to moderate Alzheimer's
.
A recent study using a retinal fundus imaging system reported that in individuals with MCI and AD, the regional increase in retinal spots suggests that regional amyloid deposits may represent the development of the disease
Comparison of retinal amyloid and brain amyloid
Comparison of retinal amyloid and brain amyloidDr.
Robert Rissman, professor of neuroscience at the University of California, San Diego School of Medicine, said: "But these findings are encouraging because they show that it is possible to use retinal imaging tests to determine the onset, spread, and morphology of Alzheimer’s disease, rather than through Expensive brain scans
.
We look forward to seeing the results of retinal scans at different times, and the impact of Solanezumab monoclonal antibody on retinal imaging
They show that it is possible to use retinal imaging tests to determine the onset, spread, and morphology of Alzheimer's disease, rather than through expensive brain scans
Reference materials:
Jennifer Ngolab et al, Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring (2021).
Jennifer Ngolab et al, Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring (2021).
DOI: 10.
1002/dad2.
12199 Jennifer Ngolab et al, Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring (2021).
DOI: 10.
1002/dad2 .
12199 Leave a message here